Published in Nat Rev Cancer on November 01, 2015
Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes Dev (2016) 0.82
ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. Mol Oncol (2017) 0.80
Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol (2016) 0.80
Dietary Natural Products for Prevention and Treatment of Liver Cancer. Nutrients (2016) 0.80
Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer (2016) 0.79
Genetic lineage tracing analysis of the cell of origin of hepatotoxin-induced liver tumors in mice. Hepatology (2016) 0.76
Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. Visc Med (2016) 0.75
Ruthenium Complexes Induce HepG2 Human Hepatocellular Carcinoma Cell Apoptosis and Inhibit Cell Migration and Invasion through Regulation of the Nrf2 Pathway. Int J Mol Sci (2016) 0.75
Identification of MicroRNAs Involved in Growth Arrest and Apoptosis in Hydrogen Peroxide-Treated Human Hepatocellular Carcinoma Cell Line HepG2. Oxid Med Cell Longev (2016) 0.75
Blocking the Ccl2-Ccr2 axis using Ccl2 neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Mol Cancer Ther (2016) 0.75
Modeling Gene Regulation in Liver Hepatocellular Carcinoma with Random Forests. Biomed Res Int (2016) 0.75
MicroRNA-148a deficiency promotes hepatic lipid metabolism and hepatocarcinogenesis in mice. Cell Death Dis (2017) 0.75
YAP determines the cell fate of injured mouse hepatocytes in vivo. Nat Commun (2017) 0.75
Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
Hepatocellular carcinoma. Lancet (2012) 18.09
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med (2012) 3.96
High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet (2011) 3.86
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
Stem cells and liver regeneration. Gastroenterology (2009) 3.40
NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2011) 3.28
Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am J Pathol (1997) 3.15
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet (2012) 3.14
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol (2015) 2.98
A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis (1987) 2.98
Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev (2013) 2.96
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 2.83
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet (2013) 2.83
Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev (2012) 2.82
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2014) 2.77
The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol (2014) 2.74
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med (2013) 2.70
THE PATHOGENESIS OF TUMORS OF THE LIVER PRODUCED BY BUTTER YELLOW. J Exp Med (1944) 2.68
TWEAK induces liver progenitor cell proliferation. J Clin Invest (2005) 2.68
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science (2014) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest (2012) 2.26
Hippo pathway activity influences liver cell fate. Cell (2014) 2.24
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet (2015) 2.17
Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes Dev (2011) 2.17
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06
Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82
A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut (2013) 1.80
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol (2014) 1.76
Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology (2007) 1.74
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Hepatic fibrosis: Concept to treatment. J Hepatol (2015) 1.68
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol (2014) 1.67
Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol (2005) 1.66
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology (2014) 1.64
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist (2014) 1.61
Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell (2014) 1.61
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet (2014) 1.60
Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology (2014) 1.59
Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology (1992) 1.58
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology (2014) 1.55
Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol (2014) 1.44
Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res (2012) 1.43
From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol (2015) 1.43
Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology (2013) 1.41
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology (2014) 1.38
Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet (2012) 1.38
Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology (2013) 1.36
Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology (2014) 1.35
Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol (2011) 1.30
A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell (2013) 1.30
Mouse models of hepatocellular carcinoma. Semin Liver Dis (2010) 1.29
Ductular reaction and its diagnostic significance. Semin Diagn Pathol (1998) 1.29
Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell (2012) 1.27
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell (2014) 1.25
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun (2015) 1.22
Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling. Proc Natl Acad Sci U S A (2013) 1.20
Hepatic stellate cells: partners in crime for liver metastases? Hepatology (2011) 1.17
EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol (2014) 1.16
Carcinoma of the liver in rats fed ethionine. AMA Arch Pathol (1956) 1.13
Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol (2000) 1.12
Clonorchiasis. Lancet (2015) 1.09